Get started

Financials · COCH

Envoy Medical Inc. (COCH) financials

For the twelve months ended Sep 30, 2026, Envoy Medical Inc. reported $231.0K of revenue and -$20.85M of net income.

Revenue, TTM
$231.0K
Revenue growth, YoY
+11.1%
Net income, TTM
-$20.85M
Net margin
-9026.4%
EPS, diluted, TTM
-$4.65
Cash
$14.57M
P/S
233.01
Market cap
$53.8M
Annual revenue$241.0K
FY2022FY2025
Annual net income-$23.76M
FY2021FY2025
Annual free cash flow-$18.38M
FY2022FY2025

COCH revenue and earnings growth

COCH revenueQ3 2026$66.0K

Quarter YoY
+57.1%
QoQ
+29.4%
FY YoY
+7.1%

COCH revenue was $66.0K in fiscal Q3 2026 (ended Sep 30, 2026), up 57.1% from a year earlier and up 29.4% from the prior quarter. For the full fiscal 2025 it was $241.0K, up 7.1% from fiscal 2024. It rose in 2 of the last 3 fiscal years.

COCH net incomeQ3 2026-$3.93M

COCH net income was -$3.93M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$6.48M a year earlier. For the full fiscal 2025 it was -$23.76M, compared with -$20.80M in fiscal 2024.

COCH EPSQ3 2026-$0.50

COCH diluted EPS was -$0.50 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was -$12.30, compared with -$14.90 in fiscal 2024.

COCH free cash flowQ3 2026-$5.06M

COCH free cash flow was -$5.06M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$4.33M a year earlier. For the full fiscal 2025 it was -$18.38M, compared with -$18.93M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
Revenue$241.0K$225.0K$316.0K$237.0K-
Cost of revenue$874.0K$742.0K$789.0K$498.0K-
Research and development$12.49M$10.18M$8.96M$4.97M-
Selling, general and admin$7.93M$6.83M$7.26M$2.58M-
Operating income-$22.27M-$19.26M-$18.36M-$8.71M-$5.20M
Interest expense$1.59M$816.0K---
Pre-tax income-$23.76M-$20.80M-$20.74M-$251.6K
Income tax---$1.50M-
Net income-$23.76M-$20.80M-$29.92M-$15.92M-$251.6K
EPS, basic-$12.30-$14.90-$25.40-$15.70-
EPS, diluted-$12.30-$14.90-$25.40-$15.70-
Diluted shares2.3M1.9M1.2M1.0M-

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
Cash and equivalents$3.74M$5.48M$4.22M$183.0K$1.12M
Receivables$34.0K$38.0K$70.0K$41.0K-
Inventory$1.55M$1.71M$1.40M$1.29M-
Current assets$6.28M$8.90M$7.46M$1.65M$863.2K
Total assets$8.56M$11.54M$8.27M$2.56M$426.90M
Current liabilities$11.56M$7.54M$7.29M$2.52M$2.68M
Long-term debt---$33.40M-
Total debt---$33.40M-
Total liabilities$20.32M$30.38M$10.05M$38.75M$38.62M
Shareholders' equity-$12.16M-$18.84M-$1.78M-$36.20M-$44.96M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
Operating cash flow-$18.20M-$17.95M-$17.09M-$8.80M-$3.24M
Capital expenditures$179.0K$980.0K$153.0K$218.0K-
Free cash flow-$18.38M-$18.93M-$17.24M-$9.02M-
Investing cash flow-$179.0K-$980.0K-$153.0K-$218.0K-$425.00M
Financing cash flow$16.63M$20.20M$21.28M$8.09M$428.37M
Dividends paid$1.82M$2.45M---
Stock-based compensation$657.0K$562.0K$1.57M--

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
Revenue growth, YoY7.1%-28.8%33.3%--
Operating margin-9240.7%-8558.2%-5809.8%-3673.4%-
Net margin-9857.3%-9242.2%-9469.0%-6718.6%-
Free cash flow margin-7626.6%-8412.9%-5457.0%-3807.2%-
Return on assets-277.6%-180.2%-361.8%-623.0%-0.1%
Current ratio0.541.181.020.650.32

Source: XBRL data Envoy Medical Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-10, first reported Nov 5, 2026.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

COCH peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
COCH$231.0K+11.1%-$20.85M-9026.4%$53.8M
ISRG$11.58B+20.5%$2.96B25.5%$155.83B
EW$6.67B+13.4%$1.02B15.3%$60.84B
STE$6.17B+8.1%$826.90M13.4%$24.89B
ZBH$8.57B+7.0%$767.30M9.0%$20.34B
MAS$7.67B+0.9%$926.00M12.1%$16.37B
SNN$6.16B+6.1%$625.00M10.1%$13.00B
ALGN$4.16B+4.4%$491.87M11.8%$12.13B
AIT$5.06B+8.5%$424.12M8.4%$11.01B

COCH FAQ

7 questions
  • What is COCH revenue?
    Envoy Medical Inc. (COCH) reported $231.0K of revenue for the twelve months ended Sep 30, 2026. That is up 11.1% from the year before. Revenue for fiscal 2025 was $241.0K.
  • Is COCH profitable?
    No. Envoy Medical Inc. reported a net loss of $20.85M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does COCH have?
    Envoy Medical Inc. reported $14.57M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is COCH revenue growing?
    Envoy Medical Inc.'s revenue changed +7.1% in fiscal 2025, to $241.0K.
  • What is COCH earnings per share?
    Diluted earnings per share were -$4.65 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did COCH last report financial results?
    The latest statements here come from Envoy Medical Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.
  • Where does this COCH financial data come from?
    Quantisnow builds these statements from the structured XBRL data Envoy Medical Inc. files with the SEC. It is provided for information only and is not investment advice.